首页> 美国卫生研究院文献>Molecular Medicine Reports >Low molecular weight heparin may benefit nephrotic remission in steroid-sensitive nephrotic syndrome via inhibiting elastase
【2h】

Low molecular weight heparin may benefit nephrotic remission in steroid-sensitive nephrotic syndrome via inhibiting elastase

机译:低分子量肝素可能通过抑制弹性蛋白酶使类固醇敏感性肾病综合征的肾病缓解受益

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Low molecular weight heparin (LMWH) has a structure similar to heparan sulfate, which exerts anti-inflammatory effects via inhibiting elastase (Ela) activity. Release of Ela along the glomerular capillary wall may induce glomerular injury and proteinuria. The present study aimed to investigate the influence of LMWH on steroid-sensitive nephrotic syndrome (SSNS) and the potential underlying mechanism. A total of 40 SSNS patients and 20 healthy controls were recruited. SSNS patients were treated with LMWH and prednisone simultaneously (LMWH+pred group) or with prednisone alone (pred group). Proteinuria, urinary glycosaminoglycans (GAGs), serum Ela and urinary creatinine levels were measured. The nephrotic period of SSNS was 15.93±5.78 days. The nephrotic period of SSNS in LMWH+pred group was significantly reduced compared with the pred group (14.13±4.56 vs. 18.63±6.49 days; P<0.05). At the follow-up of the SSNS patients, there was no statistically significant difference in number of relapses between the LMWH+pred and pred groups. Proteinuria (2.51±0.97 g/24 h), urinary GAG levels (4.92±0.87 mg/mmol creatinine) and serum Ela levels (77.64±10.99 ng/l) were significantly greater in the nephrotic period of SSNS compared with the remission period (0.107±0.026 g/24 h, 1.53±0.27 mg/mmol Cr and 41.92±7.81 ng/l, respectively) and the healthy control group (0.098±0.027 g/24 h, 1.40±0.26 mg/mmol creatinine and 38.43±9.83 ng/l, respectively; P<0.05). During the remission period, urinary GAG and serum Ela levels in the LMWH+pred group were significantly reduced compared with the pred group (P<0.05), whereas proteinuria did not differ between these groups (P>0.05). Positive correlations were revealed between urinary GAG excretion and proteinuria (r=0.877; P<0.05), proteinuria and serum Ela levels (r=0.844; P<0.05) and serum Ela levels and urinary GAG excretion (r=0.881; P<0.05). The results of the present study indicated that elevated serum Ela levels may induce proteinuria by degrading GAGs in the glomerular basement membrane in children with SSNS. LMWH may benefit nephrotic remission of SSNS via inhibiting Ela.
机译:低分子量肝素(LMWH)具有类似于硫酸乙酰肝素的结构,它通过抑制弹性蛋白酶(Ela)活性发挥抗炎作用。沿肾小球毛细血管壁释放Ela可能引起肾小球损伤和蛋白尿。本研究旨在调查LMWH对类固醇敏感性肾病综合征(SSNS)的影响及其潜在的潜在机制。总共招募了40名SSNS患者和20名健康对照。 SSNS患者同时接受LMWH和泼尼松治疗(LMWH +泼尼松组)或仅接受泼尼松治疗(泼尼松组)。测量蛋白尿,尿糖胺聚糖(GAG),血清Ela和尿肌酐水平。 SSNS的肾病期为15.93±5.78天。 LMWH + pred组SSNS的肾病期较pred组显着减少(14.13±4.56 vs. 18.63±6.49天; P <0.05)。在对SSNS患者进行随访时,LMWH + pred组和pred组之间的复发次数无统计学差异。与缓解期相比,SSNS肾病期的蛋白尿(2.51±0.97 g / 24 h),尿GAG水平(4.92±0.87 mg / mmol肌酐)和血清Ela水平(77.64±10.99 ng / l)显着更高( 0.107±0.026 g / 24 h,1.53±0.27 mg / mmol Cr和41.92±7.81 ng / l)和健康对照组(0.098±0.027 g / 24 h,1.40±0.26 mg / mmol肌酐和38.43±9.83分别为ng / l; P <0.05)。在缓解期,LMWH + pred组的尿中GAG和血清Ela水平较pred组显着降低(P <0.05),而蛋白尿在这两组之间没有差异(P> 0.05)。尿GAG排泄与蛋白尿(r = 0.877; P <0.05),蛋白尿和血清Ela水平(r = 0.844; P <0.05)和血清Ela水平与尿GAG排泄(r = 0.881; P <0.05)之间呈正相关)。本研究的结果表明,升高的血清Ela水平可能通过降解SSNS儿童肾小球基底膜中的GAGs来诱导蛋白尿。 LMWH可能通过抑制Ela而有益于SSNS的肾病缓解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号